Verve Revenue Per Share from 2010 to 2024
| VERV Stock | USD 4.60 0.05 1.10% |
Revenue Per Share | First Reported 2010-12-31 | Previous Quarter 0.18321737 | Current Value 0.19 | Quarterly Volatility 0.05303462 |
Check Verve Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Verve Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 22.4 M, Interest Income of 8.3 M or Depreciation And Amortization of 3.3 M, as well as many indicators such as Price To Sales Ratio of 72.28, Dividend Yield of 0.0 or PTB Ratio of 1.57. Verve financial statements analysis is a perfect complement when working with Verve Therapeutics Valuation or Volatility modules.
Verve | Revenue Per Share |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Verve Stock Analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.